Convergence Investment Partners LLC Sells 6,711 Shares of AngioDynamics, Inc. (ANGO)

Convergence Investment Partners LLC lessened its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 6.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,909 shares of the medical instruments supplier’s stock after selling 6,711 shares during the quarter. Convergence Investment Partners LLC owned 0.25% of AngioDynamics worth $1,554,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Stevens Capital Management LP grew its stake in shares of AngioDynamics by 0.8% in the 2nd quarter. Stevens Capital Management LP now owns 24,488 shares of the medical instruments supplier’s stock worth $397,000 after acquiring an additional 188 shares in the last quarter. Acrospire Investment Management LLC grew its stake in shares of AngioDynamics by 3.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock worth $145,000 after acquiring an additional 317 shares in the last quarter. Rothschild Asset Management Inc. grew its stake in shares of AngioDynamics by 0.3% in the 2nd quarter. Rothschild Asset Management Inc. now owns 116,912 shares of the medical instruments supplier’s stock worth $1,895,000 after acquiring an additional 357 shares in the last quarter. Comerica Bank grew its stake in shares of AngioDynamics by 2.5% in the 2nd quarter. Comerica Bank now owns 36,068 shares of the medical instruments supplier’s stock worth $606,000 after acquiring an additional 893 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its stake in shares of AngioDynamics by 6.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 13,900 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 95.29% of the company’s stock.

Several analysts have recently issued reports on the stock. Canaccord Genuity reiterated a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a research note on Sunday, October 8th. Zacks Investment Research upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Tuesday, October 3rd. KeyCorp restated a “hold” rating on shares of AngioDynamics in a research report on Friday, September 29th. Finally, BidaskClub upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. AngioDynamics currently has an average rating of “Hold” and a consensus price target of $18.60.

AngioDynamics, Inc. (NASDAQ:ANGO) opened at $17.17 on Wednesday. The firm has a market cap of $620.13, a PE ratio of 24.48, a P/E/G ratio of 1.73 and a beta of 1.04. The company has a current ratio of 2.34, a quick ratio of 1.48 and a debt-to-equity ratio of 0.17. AngioDynamics, Inc. has a 1 year low of $14.80 and a 1 year high of $18.85.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The company had revenue of $85.40 million for the quarter, compared to the consensus estimate of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. AngioDynamics’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS. equities analysts forecast that AngioDynamics, Inc. will post 0.65 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/12/06/convergence-investment-partners-llc-sells-6711-shares-of-angiodynamics-inc-ango.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply